Sebaceous Carcinoma
Sebaceous carcinoma (SC) is a rare but aggressive malignant tumor of the skin appendages that arises from sebaceous gland cells (sebocytes). It is divided into two main groups by location: ocular (periocular) SC, which accounts for about 75% of cases and usually starts in the meibomian glands or the glands of Zeis, and extraocular SC, which appears on the head, face, neck or trunk. Because it grows quietly, sebaceous carcinoma is easily mistaken in the clinic for benign problems such as a chalazion, a stye or long-standing blepharitis, or for other skin cancers. Unless it is diagnosed and treated definitively at an early stage, the tumor carries a high risk of local recurrence, deep invasion and spread to regional lymph nodes and distant organs.
At Haute-Derma, we combine detailed microscopic diagnosis, margin-controlled micrographic surgery and a multidisciplinary team approach so that patients have the tumor fully removed, receive an accurate assessment of their risk of spread, and recover as much facial function and appearance as possible.
Pathogenesis and Clinical Features
- Classification by site:
- Eyelid (ocular SC): a firm, painless nodule, most often on the upper lid (which has more meibomian glands), pale yellow or red in color. It is easily misdiagnosed as a recurrent chalazion or chronic blepharoconjunctivitis.
- Outside the eyelid (extraocular SC): a raised, firm papule or plaque measuring from 1.0 cm to more than 4.0 cm, pink-red or yellow-gray, which readily ulcerates, bleeds and forms a keratotic crust.
- Invasiveness and pagetoid spread: the most dangerous feature of ocular SC is the ability of tumor cells, singly or in clusters, to creep through the eyelid epidermis and conjunctival epithelium (pagetoid spread). This makes it very hard to judge the surgical margins by eye.
- Risk of metastasis: regional lymph node metastasis (preauricular, submandibular and cervical nodes) occurs in 10–25% of cases, and advanced tumors can spread to the lungs, liver and bone.
Histopathologic Features
- Infiltrative pattern: irregular lobules, nests or cords of malignant epithelial cells invade deep into the dermis and subcutis, and sometimes into the orbicularis muscle, tarsal plate or periosteum.
- Tumor cell morphology:
- Malignant sebocytes: abundant foamy or vacuolated cytoplasm filled with lipid droplets, and large, irregular nuclei with prominent nucleoli.
- Basaloid cells: smaller cells with basophilic nuclei, found at the periphery of the lobules or making up most of the tumor in poorly differentiated cases.
- High-grade features: very high mitotic activity with many atypical mitoses, comedo-type necrosis in the center of the lobules, perineural invasion and angiolymphatic invasion.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Distinguishing Histologic Features | Immunohistochemical Markers (IHC) |
|---|---|---|
| Sebaceous carcinoma | Nests of malignant foamy/basaloid cells, comedo necrosis, pagetoid spread, high mitotic rate. | Adipophilin (+) in a granular perinuclear pattern; EMA (+); AR (androgen receptor) (+); Ki-67 (> 40–60%); BerEP4 (−/weak). |
| Clear cell squamous cell carcinoma (SCC) | Atypical cells with intercellular bridges, obvious keratinization, no intracytoplasmic lipid droplets. | Adipophilin (−); p63/p40 strongly and diffusely (+); AR (−). |
| Basal cell carcinoma (BCC) with sebaceous differentiation | Peripheral palisading and prominent stromal retraction. | BerEP4 strongly and diffusely (+); adipophilin positive only in small focal areas. |
| Sebaceoma / sebaceous adenoma | Well-circumscribed lobules, no marked nuclear atypia, no invasion, no atypical mitoses. | Low Ki-67 (< 10–15%); normal p53; MMR protein expression retained. |
Our Approach to Treating Sebaceous Carcinoma
Led by specialists in dermatology and oncology, Haute-Derma uses a comprehensive, multimodal treatment strategy:
- Microscopic mapping and assessment of pagetoid spread: map biopsies of the eyelid and conjunctiva to define exactly how far the cancer extends before surgery.
- Mohs micrographic surgery (MMS) first: complete microscopic examination of the surgical margins to clear as much tumor as possible while sparing healthy eyelid tissue and facial structures.
- Staging and sentinel lymph node assessment (SLNB): ultrasound and other imaging to look for regional node involvement in large tumors (> 1–2 cm) or those with marked atypia.
- Genetic and whole-body screening: MMR protein staining to screen for Muir-Torre syndrome, plus a long-term follow-up plan.
How We Diagnose Sebaceous Carcinoma at Haute-Derma
To make sure no lesion is missed and the disease is staged accurately, Haute-Derma follows a rigorous diagnostic pathway:
- Clinical examination and detailed dermoscopy: assessing the nodule, any ulceration and abnormal vessels; carefully examining the eyelids, everting the lids to inspect the conjunctiva, and palpating the preauricular, submandibular and cervical lymph nodes.
- Full-thickness biopsy: a sample deep enough (including deep dermis or tarsal plate) to show how far the tumor has invaded the underlying structures.
- Baseline immunohistochemistry (IHC): a panel of adipophilin, EMA, AR, BerEP4, p63 and Ki-67 to confirm the diagnosis and reliably distinguish it from SCC and BCC.
- MMR immunostaining (Muir-Torre protocol): staining for the four markers MLH1, MSH2, MSH6 and PMS2 to screen for an inherited gene defect.
- Staging imaging: ultrasound of the facial and neck lymph nodes, MRI of the orbit or head and neck, or whole-body CT/PET-CT when the risk of metastasis is high.
How the Condition Is Treated at Haute-Derma
Our treatment plan for sebaceous carcinoma aims to eradicate the tumor and achieve the best possible functional and cosmetic result:
- Mohs micrographic surgery (MMS):
- The internationally recognized gold standard for sebaceous carcinoma of the eyelid, head and neck.
- The surgeon removes the tumor and examines the entire margin under the microscope in the operating room, repeating until the margins are completely clear (R0). This brings the recurrence rate down to below 5–8%.
- Wide local excision (WLE):
- Used for lesions outside the eyelid when Mohs surgery is not available.
- A safety margin of 0.5–1.0 cm from the visible edge of the tumor is required, extending down to the deep fascia or periosteum.
- Regional lymph node assessment and surgery: sentinel lymph node biopsy (SLNB), or regional lymph node dissection when imaging or histology shows nodal involvement.
- Radiotherapy and adjuvant systemic therapy: adjuvant radiotherapy is added for extensive tumors that cannot be removed with clear (R0) margins, tumors with significant perineural or vascular invasion, and lesions that keep recurring.
- Reconstruction and functional restoration: once the margins are confirmed clear, complex skin flaps and cartilage or conjunctival grafts are used to rebuild the eyelid, protecting the eye and restoring a natural appearance.
